- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07883577
A Study of RO7821657 in Participants With Solid Tumors
A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors
The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])
The study consists of two parts, namely Part 1 and Part 2:
Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).
Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
연구 연락처 백업
- 이름: Reference Study ID Number: BP46447 https://forpatients.roche.com/
- 전화번호: 888-662-6728
- 이메일: global-roche-genentech-trials@gene.com
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Life expectancy estimated by the Investigator to be ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
- Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
- Availability of archival tumor tissue or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
- Adequate cardiovascular function:
New York Heart Association (NYHA) Heart Failure Class ≤ 1.
- Agreement to adhere to the contraception requirements.
Exclusion Criteria:
-
Participants with active Central Nervous System (CNS) metastases.
-
Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or checkpoint inhibitor therapy or surgical procedure, greater than CTCAE Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.
a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.
-
History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.
-
Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.
-
Active autoimmune disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring immunosuppressive therapy while on study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1A: Dose Escalation
Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
실험적: Part 1B: Backfill Cohorts
Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
실험적: Part 1C: Dose Expansion/Optimization
Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
실험적: Part 2A: Abbreviated Dose Escalation
Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
실험적: Part 2B: Dose Expansion/Optimization
Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Incidence and Severity of Adverse Events (AEs)
기간: Up to approximately 27 months
|
AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria |
Up to approximately 27 months
|
|
Part 2: Incidence and Severity of Adverse Events (AEs)
기간: Up to approximately 27 months
|
AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria |
Up to approximately 27 months
|
|
Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)
기간: From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Part 2A: Nature and Frequency of DLTs
기간: From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
|
Part 2A: RP2D Range of RO7821657
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Parts 1 and 2: Serum Concentration of RO7821657
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Objective Response Rate (ORR)
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Disease Control Rate (DCR)
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Duration of Response (DoR)
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Progression-free Survival (PFS)
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: PFS Rate
기간: At 6 months
|
At 6 months
|
|
Parts 1 and 2: Overall Survival (OS) Rate
기간: At 6 months
|
At 6 months
|
|
Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)
기간: Up to approximately 27 months
|
Up to approximately 27 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trials, Hoffmann-La Roche
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- BP46447
- 2026-526150-14-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .